Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of AMD3100 in Combination With Pembrolizumab in Head and Neck Squamous Cell Carcinoma Patients Who Have Progressed on Immune Checkpoint Blockade Therapy

Next Previous
Search
Trial Profile

A Phase II Study of AMD3100 in Combination With Pembrolizumab in Head and Neck Squamous Cell Carcinoma Patients Who Have Progressed on Immune Checkpoint Blockade Therapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Plerixafor (Primary)
  • Indications Carcinoma; Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 03 Sep 2020 Planned End Date changed from 31 Aug 2024 to 11 Oct 2019.
    • 03 Sep 2020 Planned primary completion date changed from 31 Aug 2022 to 11 Oct 2019.
    • 03 Sep 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top